TY - JOUR T1 - Intra-host evolution during SARS-CoV-2 persistent infection JF - medRxiv DO - 10.1101/2020.11.13.20231217 SP - 2020.11.13.20231217 AU - Carolina M Voloch AU - Ronaldo da Silva F, Jr AU - Luiz G P de Almeida AU - Otavio J. Brustolini AU - Cynthia C Cardoso AU - Alexandra L Gerber AU - Ana Paula de C Guimarães AU - Isabela de Carvalho Leitão AU - Diana Mariani AU - Victor Akira Ota AU - Covid19-UFRJ Workgroup AU - LNCC-Workgroup AU - Cristiano X Lima AU - Mauro M Teixeira AU - Ana Carolina F Dias AU - Rafael Mello Galliez AU - Débora Souza Faffe AU - Luís Cristóvão Pôrto AU - Renato S Aguiar AU - Terezinha M P P Castiñeira AU - Orlando C. Ferreira AU - Amilcar Tanuri AU - Ana Tereza R de Vasconcelos Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/16/2020.11.13.20231217.abstract N2 - Prolonged infection of SARS-CoV-2 represents a challenge to the development of effective public health policies to control the COVID-19 pandemic. The reason why some people have persistent infection and how the virus survives for so long are still not fully understood. For this reason, we aimed to investigate the intra-host evolution of SARS-CoV-2 during persistent infection. Thirty-three patients who remained RT-PCR positive in the nasopharynx for at least 16 days were included in this study. Complete SARS-CoV-2 sequences were obtained for each patient at two time points. Phylogenetic, populational, and computational analysis of viral sequences confirmed persistent infection with evidence for a transmission cluster in health care professionals that shared the same workplace. A high number of missense variants targeting crucial structural and non-structural proteins such as Spike and Helicase was found. Interestingly, longitudinal acquisition of substitutions in Spike protein mapped many SARS-CoV-2 predicted T cell epitopes. Furthermore, the mutational profiles observed were suggestive of RNA editing enzyme activities, indicating innate immune mechanisms of the host cell. Viral quasispecies analysis corroborates persistent infection mainly by increasing richness and nucleotide diversity over time. Altogether, our findings highlight a dynamic and complex landscape of host and pathogen interaction during persistent infection suggesting that the host’s innate immunity shapes the increase of intra-host diversity with possible implications for therapeutic strategies and public health decisions during the COVID-19 pandemic.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNational Commission of Ethics in Research 30161620.0.0000.5257 National Commission of Ethics in Research 30127020.0.0000.0068Funding StatementThis work was developed in the frameworks of Corona-omica-RJ (FAPERJ = E-26/210.179/2020) and Rede Corona-omica BR MCTI/FINEP (FINEP = 01.20.0029.000462/20, CNPq = 404096/2020-4). The study was also supported by FAPERJ E-26/010.002434/2019 and E-26/210.178/2020 for A.T, and E-26/010.002278/2019 for C.M.V. A.T.R.V. is supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq (303170/2017-4) and FAPERJ (E-26/202.903/20). R.S.F.J is a recipient of a graduate fellowship from CNPq. C.C.C is supported by FAPERJ (E-26/202.791/2019).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The present study was approved by the National Commission of Ethics in Research (protocol numbers 30161620.0.0000.5257 and 30127020.0.0000.0068). Written informed consent was obtained from all participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNGS data generated in our study is publicly available in SRA-NCBI (www.ncbi.nlm.nih.gov/sra), Bioproject accession PRJNA675840. Genome sequences are also deposited in Gisaid (www.gisaid.org) and the access identifiers are listed in Table S1. ER -